Irritable Bowel Syndrome - Pipeline Review, H2 2015 Is Released Irritable Bowel Syndrome - Pipeline Review, H2 2015 Summary Global Markets Direct s, Irritable Bowel Syndrome - Pipeline Review, H2 2015, provides an overview of the Irritable Bowel Syndrome s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Irritable Bowel Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Irritable Bowel Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Irritable Bowel Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Irritable Bowel Syndrome - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Irritable Bowel Syndrome pipeline depth and focus of Indication 1
therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Browse Complete Report with TOC http://www.idatainsights.com/reports-landingpage.php?id=179113/irritable-bowel-syndrome-pipeline-review-h2-2015 To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landingpage.php?id=179113/irritable-bowel-syndrome-pipeline-review-h2-2015 Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Irritable Bowel Syndrome Overview 9 Therapeutics Development 10 Pipeline Products for Irritable Bowel Syndrome - Overview 10 Irritable Bowel Syndrome - Therapeutics under Development by Companies 11 Irritable Bowel Syndrome - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Irritable Bowel Syndrome - Products under Development by Companies 16 Irritable Bowel Syndrome - Companies Involved in Therapeutics Development 18 4D Pharma Plc 18 A. Menarini Industrie Farmaceutiche Riunite Srl 19 Alba Therapeutics Corporation 20 2
Alfa Wassermann S.p.A 21 Allergan Plc 22 Ardelyx, Inc. 23 Astellas Pharma Inc. 24 CJ HealthCare Corp. 25 Dong-A Socio Group 26 Enterome Bioscience SA 27 ImmusanT, Inc. 28 Ironwood Pharmaceuticals, Inc. 29 Ono Pharmaceutical Co., Ltd. 30 Pfizer Inc. 31 Protagonist Therapeutics Inc. 32 RaQualia Pharma Inc. 33 SK Biopharmaceuticals Co., Ltd. 34 SK Chemicals Co., Ltd. 35 Sumitomo Dainippon Pharma Co., Ltd. 36 Synergy Pharmaceuticals, Inc. 37 Synthetic Biologics, Inc. 38 Takeda Pharmaceutical Company Limited 39 Yuhan Corporation 40 Irritable Bowel Syndrome - Therapeutics Assessment 41 Assessment by Monotherapy Products 41 Assessment by Target 42 3
Assessment by Mechanism of Action 44 Assessment by Route of Administration 46 Assessment by Molecule Type 48 Drug Profiles 50 ASP-1017 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 ASP-7147 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Blautix - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 crofelemer DR - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 DA-6886 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 4
DSP-6952 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 EB-120 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 eluxadoline - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 ibodutant - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 larazotide acetate - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 linaclotide - Drug Profile 63 Product Description 63 Mechanism of Action 63 5
R&D Progress 63 Nexvax-2 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 ONO-2952 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 PBF-677 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 plecanatide - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 pregabalin - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 relenopride hydrochloride - Drug Profile 72 Product Description 72 Mechanism of Action 72 6
R&D Progress 72 rifaximin - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 RQ-00202730 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 RQ-00310941 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 SKI-3246 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Small Molecule to inhibit IBAT for Chronic Constipation and Irritable Bowel Syndrome - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile 79 Product Description 79 7
Mechanism of Action 79 R&D Progress 79 solabegron hydrochloride - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 SYN-010 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Synthetic Peptide for Irritable Bowel Syndrome with Diarrhea - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 TAK-480 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 tenapanor hydrochloride - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 YH-12852 - Drug Profile 88 Product Description 88 8
Mechanism of Action 88 Read More http://www.idatainsights.com/reports-landing-page.php?id=179113/irritable-bowelsyndrome-pipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.
9